Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma

Inclusion Criteria: * ECOG PS≤1; * pathologically confirmed adenocarcinoma of bile duct; * R1 resection or R0 resection with these risk factors: lymph node metastasis, lymphatic vessel or blood vessel invasion, multiple tumors, tumor size \>5 cm, preoperative CA199\>200 U/mL. * postoperative liver function Child Pugh Class A, leukocyte count\>1.5\*10\^9/L, platelet count\>100\*10\^9/L, serum alanine aminotransferase \<1.5\*ULN * no tumor recurrence or metastasis on baseline examination * no history of radiotherapy or intervention therapy Exclusion Criteria: * hepatocellular carcinoma, mixed carcinoma of ICC and HCC, or hilar cholangiocarcinoma * distant metastasis * prothrombin time \>14s * severe cardiopulmonary dysfunction * severe renal dysfunction * bone marrow suppression before the initiation of therapy * allergic to fluorouracil, gemcitabine, or platinum * gemcitabine was used in combination with radiotherapy